Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia

• DOI: 10.1038/s41467-020-19774-x
• Publication Date: 2020-11-23T11:08:30Z
• Authors: Furun An; Huiping Wang; Zhenyun Liu; Fan Wu; Jiakui Zhang; Qianshan Tao; Yingwei Li; Yuanyuan Shen; Yanjie Ruan; Qing Zhang; Ying Pan; Weiwei Zhu; Hui Qin; Yansheng Wang; Yongling Fu; Zhenqing Feng; Zhimin Zhai
• Keywords: Refractory (planetary science)

Abstract CD19-specific chimeric antigen receptor T cell (CD19 CAR T) therapy has shown high remission rates in patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL). However, the long-term outcome and factors that influence efficacy need further exploration. Here we report of 51 r/r B-ALL from a non-randomized, Phase II clinical trial (ClinicalTrials.gov number: NCT02735291). The primary shows overall rate (complete or without incomplete hematologic recovery) is 80.9%. secondary reveals survival (OS) relapse-free (RFS) at 1 year are 53.0 45.0%, respectively. incidence grade 4 adverse reactions 6.4%. meets pre-specified endpoints. Further analysis extramedullary diseases (EMDs) other than central nervous system (CNS) involvement have lowest (28.6%). OS RFS any subtype EMDs, higher Tregs, high-risk genetic all significantly lower their corresponding control cohorts. EMDs Tregs independent respectively for poor RFS. Thus, these patient characteristics may hinder therapy.